Programme Category
Programme Name
Programme Description
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Identifier Code
Call
Summary
The partnership should facilitate exchange of information and good practices among countries, provide robust guidance and tools, will network institutional stakeholders and involve regional ecosystems. It should stimulate service, policy and organisational innovations, as well as the integration of biomedical and technological innovations for the benefit of the European citizens and the European industry. The partnership should bring together a broad range of actors with a common vision of future personalised medicine. Through the objectives of Horizon Europe, the partnership should contribute to achieving the following European Commission priorities:
- Promoting our European way of life
- An economy that works for people
- A Europe fit for the digital age
- A European green deal
Detailed Call Description
Τhe partnership should address the following objectives:
- Putting Europe at the forefront of research and innovation through the support of multidisciplinary actions open to international cooperation;
- Establishing a European national and regional network of research and innovation systems dedicated to personalised medicine;
- Translating basic research into clinical applications that make a difference for patients, their families and healthcare professionals;
- Filling scientific knowledge gaps, producing evidence and developing guidance and tools in priority areas for the development and the deployment of personalised medicine;
- Integrating big data and digital health solutions in research and personalised healthcare;
- Strengthening the European healthcare industry and accelerating the uptake of personalised medicine solutions;
- Developing appropriate ecosystems for the implementation of successful personalised medicine approaches and a swift uptake of relevant innovations by healthcare systems;
- Providing socio-economic evidence of the feasibility of personalised medicine approaches for its uptake by sustainable healthcare systems;
- Improving health outcomes for citizen and patients and ensuring a wide access to advanced personalised medicine intervention approaches to all.
The Partnership’s governance structure should enable an upfront strategic steering, effective management and coordination, daily implementation of activities and ensure the use and uptake of the results. The governance should leave sufficient space for involving the key stakeholders, including but not limited to R&I community, patients and citizens, healthcare professionals, formal and informal care organisations, and innovation owners.
Beneficiaries – may provide financial support to third parties. The support to third parties can only be provided in the form of grants. Financial support provided by the participants to third parties is one of the primary activities of the action in order to be able to achieve its objectives. Given the type of action and its level of ambition, the maximum amount to be granted to each third party is €10,00 million.
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
30%
Contribution per project: €50,00 million
Thematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Associations
- International Organisations
- Natual person / Citizen / Individual
- NGOs
- Non Profit Organisations
- Other Beneficiaries
- Private Bodies
- Researchers/Research Centers/Institutions
- Semi-governmental organisations
- State-owned Enterprises
Eligibility For Participation Notes
The governance should leave sufficient space for involving the key stakeholders, including but not limited to R&I community, patients and citizens, healthcare professionals, formal and informal care organisations, and innovation owners.
The Partnership is open to all EU Member States, as well as to countries associated to Horizon Europe and will remain open to third countries wanting to join. It should include the following actors:
- Ministries in charge of R&I policy, as well as national and regional R&I and technology funding agencies and foundations;
- Ministries in charge of health and care policy, as well as national and regional healthcare authorities, organisations and providers.
The Partnership may also encourage engagement with other relevant Ministries and will involve other key actors from civil society and end-users, research and innovation community, innovation owners, healthcare systems owners/organisers and healthcare agencies.
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding. Because the US contribution will be considered for the calculation of the EU contribution to the partnership, the concerned consortium of research funders from eligible EU Members States and Associated Countries must expressly agree to this participation.
The Joint Research Centre (JRC) may participate as member of the consortium selected for funding.
Call Opening Date
Call Closing Date
National Contact Point(s)
Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia
P.O.Box 23422, 1683 Nicosia
Telephone: +357 22205000
Email Address: support@research.org.cy
Website: https://www.research.org.cy/en/
Contact Persons:
George Christou
Scientific Officer
Email: gchristou@research.org.cy
Ioannis Theodorou
Scientific Officer
Telephone: +357 22 205 038
Contact Email: itheodorou@research.org.cy
(Publish Date: 08/02/2023-for internal use only)
EU Contact Point
European Commission, Directorate-General for Research and Innovation
https://ec.europa.eu/info/departments/research-and-innovation_en#contact